Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next year. This suggests that the stock has a possible downside of 0.6%.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.

Teva Pharmaceutical Industries' stock was trading at $9.12 at the beginning of the year. Since then, TEVA shares have increased by 17.7% and is now trading at $10.73.
View the best growth stocks for 2023 here.

Teva Pharmaceutical Industries saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 25,020,000 shares, a decrease of 20.5% from the December 31st total of 31,470,000 shares. Based on an average trading volume of 9,750,000 shares, the days-to-cover ratio is currently 2.6 days.
View Teva Pharmaceutical Industries' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our TEVA earnings forecast.

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its earnings results on Wednesday, October, 27th. The company reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.65 by $0.06. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $4.05 billion. Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive trailing twelve-month return on equity of 26.97%. Teva Pharmaceutical Industries's revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.56 earnings per share.

Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of $2.40-$2.60 for the period, compared to the consensus EPS estimate of $2.50. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.46 billion.

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (1.94%), Harel Insurance Investments & Financial Services Ltd. (1.36%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), AustralianSuper Pty Ltd (0.22%), Simplex Trading LLC (0.00%) and Private Management Group Inc. (0.12%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $10.73.

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $11.92 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($1.16) on an earnings per share basis.

The company employs 37,537 workers across the globe.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.